Abstract
The second messenger diacylglycerol (DAG) plays a central role in the signal transduction of G-protein coupled receptors and receptor tyrosine kinases by binding to C1 domain of effector proteins. C1 domain was first identified in protein kinase C (PKC) which comprises a family of ten isoforms that play roles in diverse cellular processes such as proliferation, apoptosis and differentiation. Aberrant signaling through PKC isoforms and other C1 domain-containing proteins has been implicated in several pathological disorders. Drug discovery concerning C1 domains has exploited both natural products and rationally designed compounds. Currently, molecules from several classes of C1 domain-binding compounds are in clinical trials; however, still more have the potential to enter the drug development pipeline. This review gives a summary of the recent developments in C1 domain-binding compounds.
Keywords: Protein kinase C, C1 domain, drug discovery, cancer, Alzheimer's disease, bryostatins, ingenol-3-angelate, DAGlactones, signal transduction of G-protein, PKC, drug development pipeline, C1 domain-binding compounds
Current Topics in Medicinal Chemistry
Title: Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Volume: 11 Issue: 11
Author(s): Gustav Boije af Gennas, Virpi Talman, Jari Yli-Kauhaluoma, Raimo K Tuominen and Elina Ekokoski
Affiliation:
Keywords: Protein kinase C, C1 domain, drug discovery, cancer, Alzheimer's disease, bryostatins, ingenol-3-angelate, DAGlactones, signal transduction of G-protein, PKC, drug development pipeline, C1 domain-binding compounds
Abstract: The second messenger diacylglycerol (DAG) plays a central role in the signal transduction of G-protein coupled receptors and receptor tyrosine kinases by binding to C1 domain of effector proteins. C1 domain was first identified in protein kinase C (PKC) which comprises a family of ten isoforms that play roles in diverse cellular processes such as proliferation, apoptosis and differentiation. Aberrant signaling through PKC isoforms and other C1 domain-containing proteins has been implicated in several pathological disorders. Drug discovery concerning C1 domains has exploited both natural products and rationally designed compounds. Currently, molecules from several classes of C1 domain-binding compounds are in clinical trials; however, still more have the potential to enter the drug development pipeline. This review gives a summary of the recent developments in C1 domain-binding compounds.
Export Options
About this article
Cite this article as:
Boije af Gennas Gustav, Talman Virpi, Yli-Kauhaluoma Jari, K Tuominen Raimo and Ekokoski Elina, Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates, Current Topics in Medicinal Chemistry 2011; 11 (11) . https://dx.doi.org/10.2174/156802611795589584
DOI https://dx.doi.org/10.2174/156802611795589584 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Activation of Integrin β1 Mediates the Increased Malignant Potential of Ovarian Cancer Cells Exerted by Inflammatory Cytokines
Anti-Cancer Agents in Medicinal Chemistry Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry Advances in the Treatment of Triple-negative Early Breast Cancer
Medicinal Chemistry Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology Critical Review of the Evidence on 5-Aminosalicilate for Chemoprevention of Colorectal Cancer in Ulcerative Colitis: A Methodological Question
Current Clinical Pharmacology Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Preclinical Models to Study Breast Cancer
Clinical Cancer Drugs Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Signaling Mechanism(S) of Reactive Oxygen Species in Epithelial-Mesenchymal Transition Reminiscent of Cancer Stem Cells in Tumor Progression
Current Stem Cell Research & Therapy Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Subcellular Analysis of the Platelet Proteome
Current Proteomics Topical Calcineurin Inhibitors, Pimecrolimus and Tacrolimus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Retinoids in Cancer Chemoprevention
Current Cancer Drug Targets Stem Cell Dynamics and Heterogeneity: Implications for Epidermal Regeneration and Skin Cancer
Current Medicinal Chemistry